Our information clearly show that CK18 is constantly expressed in many epithelial cancers, Specifically adenocarcinomas. both equally loss of CK18 expression in cancers derived from CK18 beneficial precursor cells and neo-expression in malignancies derived from CK18 beneficial precursors are usually linked to unfavorable tumor phenotype and disease